You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Table TDI-8. Primary use of stimulants of clients entering treatment, 2011 or most recent year available
Part (ii) All clients by country and type of stimulant (%)
| Country | Amphetamines | % | Ecstasy | % | Other stimulants | % | Total stimulants | |
|---|---|---|---|---|---|---|---|---|
| Belgium | 1 | 581 | 91.1 | 38 | 6.0 | 11 | 1.7 | 638 |
| Bulgaria | 34 | 59.6 | 6 | 10.5 | 17 | 29.8 | 57 | |
| Czech Republic | 6008 | 99.7 | 6 | 0.1 | 13 | 0.2 | 6027 | |
| Denmark | 358 | 96.5 | 13 | 3.5 | 0 | 0.0 | 371 | |
| Germany | 2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 6501 |
| Estonia | 13 | 100.0 | : | : | : | : | 13 | |
| Ireland | 53 | 47.3 | 51 | 45.5 | 8 | 7.1 | 112 | |
| Greece | 6 | 30.0 | 9 | 45.0 | 5 | 25.0 | 20 | |
| Spain | 3 | 517 | 79.1 | 98 | 15.0 | 39 | 6.0 | 654 |
| France | 107 | 36.8 | 118 | 40.5 | 66 | 22.7 | 291 | |
| Italy | 4 | 38 | 21.7 | 129 | 73.7 | 8 | 4.6 | 175 |
| Cyprus | 2 | 10.5 | 3 | 15.8 | 14 | 73.7 | 19 | |
| Latvia | 5 | 380 | 90.3 | 2 | 0.5 | 39 | 9.3 | 421 |
| Lithuania | 2 | : | : | : | : | : | : | : |
| Luxembourg | 1 | : | : | : | : | : | 1 | |
| Hungary | 567 | 72.1 | 50 | 6.4 | 169 | 21.5 | 786 | |
| Malta | 3 | 11.1 | 13 | 48.1 | 11 | 40.7 | 27 | |
| Netherlands | 818 | 89.2 | 69 | 7.5 | 30 | 3.3 | 917 | |
| Austria | 83 | 62.4 | 19 | 14.3 | 31 | 23.3 | 133 | |
| Poland | 6 | 285 | 96.9 | 1 | 0.3 | 8 | 2.7 | 294 |
| Portugal | 7 | 1 | 14.3 | 4 | 57.1 | 2 | 28.6 | 7 |
| Romania | 12 | 57.1 | 9 | 42.9 | 0 | 0.0 | 21 | |
| Slovenia | 2 | 66.7 | 1 | 33.3 | : | : | 3 | |
| Slovakia | 784 | 99.6 | 2 | 0.3 | 1 | 0.1 | 787 | |
| Finland | 204 | 91.1 | 4 | 1.8 | 16 | 7.1 | 224 | |
| Sweden | 204 | 100.0 | 0 | 0.0 | : | : | 204 | |
| United Kingdom | 8 | 3486 | 68.5 | 229 | 4.5 | 1372 | 27.0 | 5087 |
| Croatia | 80 | 62.5 | 23 | 18.0 | 25 | 19.5 | 128 | |
| Turkey | 18 | 94.7 | 1 | 5.3 | : | : | 19 | |
| Norway | 9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1127 |
| Total | 14645 | 58.4 | 898 | 3.6 | 1885 | 7.5 | 25064 |
Notes:
: Indicates no data available
Percentages are of clients in treatment for stimulants as primary drug
(1) In Belgium if the exact primary drug is not known, the generic category is recorded.
(2) For Germany and Lithuania only the aggregated data for Stimulants Total are available.
(3) Data are from 2010.
(4) In 2011 around 27% of all clients and 32% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.
(5) In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. Caution should be made when comparing data with previous years.
(6) Data from 2010. Category amphetamines includes both amphetamine and methamphetamine. Data presented in the table come from TDI pilot project.
(7) In 2010 came into implementation a new national information system implying methodological changes particularly in the registration criteria. Caution should be made when comparing 2010 onwards data with previous years.
(8) Data are from 1st of April 2010 to 31st March 2011.
(9) In Norway the criteria for selecting and grouping cases are main ICD-10 diagnosis codes F11-F16 and F18-F19.
See also ‘General notes for interpreting data’ on the Explanatory notes and help page.
Source:
Reitox national reports 2012 — Standard table 3.